TP53 and colonic neoplasm: Colon cancer TP53‐Dox cells, which heterozygously carried R273H mutant p53 (TP53 R273/+, introduced by a CRISPR/Cas9 system in SW48 cells) and then were subjected to long‐term subchronic exposure to doxorubicin (Dox), displayed resistance to anticancer drugs.20, 22